Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Arq. bras. endocrinol. metab ; 48(3): 368-373, jun. 2004. tab
Article in Portuguese | LILACS | ID: lil-365151

ABSTRACT

Neste estudo, investigamos o potencial hipolipemiante do extrato seco do fruto de berinjela (Solanum melongena), o qual tem sido comercializado no Brasil para o tratamento da hiperlipidemia humana. Assim, um estudo duplo-cego randomizado, objetivando avaliar a eficácia da Solanum melongena (SM) administrada oralmente, foi realizado. Este estudo consistiu de 41 voluntários hiperlipidêmicos alocados para tratamento com SM (n= 21) ou placebo (n= 20). Cada voluntário recebeu duas cápsulas contendo SM (450mg) ou placebo (450mg) duas vezes ao dia, sendo acompanhados mensalmente. A dose de SM utilizada corresponde ao empregado para tratar hiperlipidemia no Brasil. Após 3 meses de tratamento, os valores séricos de colesterol total, LDL-c e LDL-c/HDL-c diminuíram (p<0,05) no grupo tratado com SM. Todavia, efeito similar foi observado no grupo placebo. Os demais parâmetros, incluindo valores séricos de triglicérides, HDL-c, VLDL-c, AST, ALT, gGT, glicose e índice de massa corpórea não apresentaram modificações significativas. Assim, podemos concluir que a SM, pelo menos na forma comercializada no Brasil (extrato seco do fruto), requer um maior volume de estudos clínicos antes de ser recomendada para tratar hiperlipidemia.


Subject(s)
Humans , Middle Aged , Fruit , Hyperlipidemias/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Solanum melongena , Double-Blind Method , Longitudinal Studies
2.
Arq Bras Endocrinol Metabol ; 48(3): 368-73, 2004 Jun.
Article in Portuguese | MEDLINE | ID: mdl-15640898

ABSTRACT

In this study we investigated the hypolipidemic potential of dried powdered fruits of eggplant (Solanum melongena), which has been commercialized in Brazil to treat human hyperlipidemia. Thus, a double-blind placebo-controlled study of the effectiveness of oral Solanum melongena (SM) was conducted. The study consisted of 41 hyperlipidemic volunteers allocated to active treatment (n= 21) or placebo (n= 20). Each volunteer received two capsules containing SM (450 mg) or placebo (450 mg) twice daily and were followed monthly. The dose of SM used corresponds to that given to treat hyperlipidemia in Brazil. After 3 months, serum total cholesterol, LDL-c and LDL-c/HDL-c decreased (p<0.05) in the group treated with SM. However similar effect was also observed in the placebo group. The other parameters, including serum triglycerides, HDL-c, VLDL-c, AST, ALT, gGT, glucose and body mass index, showed no significant changes. We conclude that SM, at least in the form commercialized in the Brazil (dried powdered fruits), require further clinical trials before being recommended to treat hyperlipidemia.


Subject(s)
Fruit , Hyperlipidemias/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Solanum melongena , Double-Blind Method , Humans , Longitudinal Studies , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...